Table 3 The pathological distribution and survival of adrenal malignancy
From: Clinical analysis of adrenal lesions larger than 5 cm in diameter (an analysis of 251 cases)
Pathology types | Number | Survival rate (%) | ||||
|---|---|---|---|---|---|---|
2 m | 6 m | 12 m | 24 m | 30 m | ||
Adrenal metastatic carcinoma | T (Mu/So) | |||||
Lung cancer | 24 (14/10) | 96 (93/100) | 58 (43/80) | 33 (14/60) | 8 (0/20) | 4 (0/10) |
Gastrointestinal cancer | 5 (4/1) | 60 (75/0) | 20 (25/0) | 0 (0/0) | 0 (0/0) | 0 (0/0) |
Liver cancer | 5 (1/4) | 80 (0/100) | 80 (0/100) | 60 (0/75) | 40 (0/50) | 20 (0/25) |
Renal carcinoma | 5 (2/3) | 80 (100/67) | 60 (50/67) | 20 (0/33) | 20 (0/33) | 20 (0/33) |
Prostate cancer | 1 (1/0) | 0 | 0 | 0 | 0 | 0 |
Pancreatic cancer | 1 (1/0) | 100 | 0 | 0 | 0 | 0 |
Renal pelvis carcinoma | 1 (1/0) | 100 | 0 | 0 | 0 | 0 |
Nose malignant melanoma | 1 (0/1) | 100 | 0 | 0 | 0 | 0 |
Primary adrenal malignancy | T (N-Me/Me) | |||||
Cortical carcinoma | 22 (13/9) | 91 (92/89) | 64 (69/56) | 45 (46/44) | 23 (31/11) | 14 (15/11) |
Small cell carcinoma | 3 (2/1) | 100 (100/100) | 100 (100/100) | 100 (100/100) | 100 (100/100) | 67 (100/0) |
Lymphoma | 3 (2/1) | 67 (100/0) | 33 (50/0) | 33 (50/0) | 33 (50/0) | 33 (50/0) |
Melanoma | 1 (0/1) | 100 | 100 | 0 | 0 | 0 |